Roche builds case for T-cell bispecific-anti-PD-L1 combo

Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer. The readout hints that the T cell-activating antibody may improve outcomes in this hard-to-treat population when given as a monotherapy and in combination with anti-PD-L1 drug Tecentriq.